Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Fluoxetine in the prevention of depressive recurrences: A double-blind study
Autore:
Gilaberte, I; Montejo, AL; de la Gandara, J; Perez-Sola, V; Bernardo, M; Massana, J; Martin-Santos, R; Santiso, A; Noguera, R; Casais, L; Perez-Camo, V; Arias, M; Judge, R;
Indirizzi:
Eli Lilly & Co Ltd, Lilly Res Ctr, European Prod Team Physician, Windlesham GU20 6PH, Surrey, England Eli Lilly & Co Ltd Windlesham Surrey England GU20 6PH PH, Surrey, England Hosp Clin Salamanca, Salamanca, Spain Hosp Clin Salamanca Salamanca Spain sp Clin Salamanca, Salamanca, Spain Hosp Gen Yague, Burgos, Spain Hosp Gen Yague Burgos SpainHosp Gen Yague, Burgos, Spain Hosp Sant Pau, Barcelona, Spain Hosp Sant Pau Barcelona SpainHosp Sant Pau, Barcelona, Spain Hosp Clin & Prov, Barcelona, Spain Hosp Clin & Prov Barcelona SpainHosp Clin & Prov, Barcelona, Spain Hosp del Mar, Barcelona, Spain Hosp del Mar Barcelona SpainHosp del Mar, Barcelona, Spain Hosp Mutua Tarrasa, Tarrasa, Spain Hosp Mutua Tarrasa Tarrasa SpainHosp Mutua Tarrasa, Tarrasa, Spain Hosp Josep Trueta, Gerona, Spain Hosp Josep Trueta Gerona SpainHosp Josep Trueta, Gerona, Spain Clin Nuestra Sra Salud, Cadiz, Spain Clin Nuestra Sra Salud Cadiz SpainClin Nuestra Sra Salud, Cadiz, Spain CSM Delicias, Zaragoza, Spain CSM Delicias Zaragoza SpainCSM Delicias, Zaragoza, Spain Hosp Xeral, Vigo, Spain Hosp Xeral Vigo SpainHosp Xeral, Vigo, Spain Lilly Res Labs, Indianapolis, IN USA Lilly Res Labs Indianapolis IN USALilly Res Labs, Indianapolis, IN USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 4, volume: 21, anno: 2001,
pagine: 417 - 424
SICI:
0271-0749(200108)21:4<417:FITPOD>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
LONG-TERM TREATMENT; SERTRALINE; EFFICACY; FLUVOXAMINE; RECOVERY; PLACEBO; RELAPSE; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Gilaberte, I Eli Lilly & Co Ltd, Lilly Res Ctr, European Prod Team Physician, Erl Wood Manor,Sunninghill Rd, Windlesham GU20 6PH, Surrey, England EliLilly & Co Ltd Erl Wood Manor,Sunninghill Rd Windlesham Surrey England GU20 6PH
Citazione:
I. Gilaberte et al., "Fluoxetine in the prevention of depressive recurrences: A double-blind study", J CL PSYCH, 21(4), 2001, pp. 417-424

Abstract

Optimal outcomes from depression treatment are long-term recovery and, in the case of recurrent depression, prevention of new episodes. However, few data are available concerning the longterm efficacy of antidepressants in prophylactic treatment to prevent recurrences of depression. The efficacy and safety of fluoxetine 20 mg/day was evaluated in reducing the number of depressive episodes and in extending the time free of symptoms in patients with recurrent unipolar major depression. Patients with recurrent unipolar major depression according to DSM-III-R criteria and who responded to 32 weeks of open-label fluoxetine were randomly assigned to receive fluoxetine 20 mg/day (N = 70) or placebo (N = 70) for 48 weeks of double-blind maintenance treatment. Outcome measures were the percentage of recurrences and time to recurrence. Safety assessments included treatment-emergent adverse events, reasons for discontinuation, vital signs, and laboratory measures. Fluoxetine was associated with a statistically significantly smaller percentage of patients who had a recurrence compared with placebo (20% vs. 40%; chi (2)analysis,p = 0.010). The symptom-free period was significantly longer for patients treated with fluoxetine versus placebo (295 vs. 192 days; Kaplan-Meier estimates, log-rank test, p = 0.002). Treatments were well tolerated during maintenance treatment. The only statistically significant difference in adverse events between treatment groups was anxiety, which was more frequent in the placebo group (fluoxetine, 12.9% vs. placebo, 30%; chi (2) analysis, p = 0.013). Two placebo-treated patients and no fluoxetine-treated patients were withdrawn because of adverse events. In conclusion, fluoxetine at 20 mg/day was effective and well tolerated for the prophylactic treatment of recurrent unipolar major depression.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 08:19:38